Live news related to ABL Diagnostics stock (FR001400AHX6): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ABL Diagnostics mainly cover M&A activity, earnings publications et analyst notes. The stock trades at €2,38 on Euronext Paris, up 5,31% at the last update. This page lists the articles published on ABL Diagnostics stock to track the share price, company announcements and any item likely to influence market perception.
The molecular diagnostics specialist based in Woippy announced in a press release issued on October 20, 2026 at 6:00 p.m. that the planned transaction…
In a press release published on October 19, 2026, the molecular diagnostics company listed in Paris relayed the intentions of Advanced Biological Labo…
In a note dated October 8, 2026, the research firm maintained its price target of 8.7€ per share on the molecular diagnostics company. The report was …
The French molecular diagnostics specialist now targets revenue between €13.5 million and €14.0 million for fiscal year 2026, potentially doubling com…
The French molecular diagnostics specialist has signed a non-binding letter of intent for the acquisition of 100% of two companies from the Vela group…
The molecular diagnostics company listed on Euronext Paris announced its participation in an institutional investors meeting organized at the end of S…
The molecular diagnostics company has submitted an offer targeting the activities and assets of IntegraGen, a genomic analysis specialist placed under…
ABL Diagnostics announced on September 10, 2026 the conclusion of a partnership between its Texcell division and Abionyx Pharma. Texcell will conduct …
In six months, ABL Diagnostics achieved 77.9% of the full-year 2025 revenue and its half-year net income exceeded by 29.7% that recorded over the twel…
ABL Diagnostics approved a dividend of €0.11 per share for the fiscal year 2025 on June 30, up from €0.05 paid for 2024, reflecting improved results a…
